No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients

다국어 초록 (Multilingual Abstract)

Background/Aims: There are few available data regarding the association between the single nucleotidepolymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) topeginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients.
Methods: This was a retrospective cohort study of 156 patients with chronic hepatitis C virus (HCV) infection whoreceived combination treatment of PEG-IFN plus RBV. Blood samples from these patients were analyzed to identifythe IL28B SNPs at rs12979860, rs12980275, rs8099917, and rs8103142. Association analyses were performed to evaluatethe relationships between each IL28B SNP and SVRs.
Results: Seventy six patients with HCV genotype 1 and 80 with genotype non-1 were enrolled. The frequencies ofrs12979860 CC and CT genotypes were 90.4% and 9.6%, respectively; those of rs12980275 AA and AG genotypes were87.2% and 12.8%, respectively; those of rs8099917 TT and TG genotypes were 92.3% and 7.7%, respectively; and thoseof rs8103142 TT and CT genotypes were 90.4% and 9.6%, respectively. Among the patients with HCV genotype 1, theSVR rates were 69.7% and 80.0% for rs12979860 CC and CT, respectively (P=0.71). Among the HCV genotype non-1patients, SVR rates were 88.0% and 100% for rs12979860 CC and CT (P=1.00), respectively.
Conclusions: Genotypes of the IL28B SNP that are known to be favorable were present in most of the Korean patientswith chronic hepatitis C in this study. Moreover, the IL28B SNP did not influence the SVR rate in either the HCVgenotype 1 or non-1 patients. Therefore, IL28B SNP analysis might be not useful for the initial assessment, predictionof treatment outcomes, or treatment decision-making of Korean chronic hepatitis C patients.

참고문헌 (Reference)

1 Huang JF, "Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan" 25 : 1029-1037, 2007

2 Asrani SK, "Predicting response to pegylated interferon/ribavirin-based therapy in genotype 1 chronic hepatitis C patients:results of 3 independent genome-wide association studies" 138 : 1622-1624, 2010

3 Lyoo K, "Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin" 52 : 363-366, 2011

4 Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose" 140 : 346-355, 2004

5 Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" 358 : 958-965, 2001

6 Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection" 347 : 975-982, 2002

7 Jung YK, "Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?" 19 : 26-28, 2013

8 Suppiah V, "IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy" 41 : 1100-1104, 2009

9 Shiratori Y, "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy" 132 : 517-524, 2000

10 Nae Yun Heo, "High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice" 대한간학회 19 (19): 60-69, 2013

11 Honda M, "Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C" 139 : 499-509, 2010

12 Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C" 41 : 1105-1109, 2009

13 Indolfi G, "Genetic variation in interleukin-28B locus is associated with spontaneous clearance of HCV in children with non-1 viral genotype infection" 54 : 1490-1491, 2011

14 Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance" 461 : 399-401, 2009

15 Rauch A, "Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study" 138 : 1338-1345, 2010

16 Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus" 461 : 798-801, 2009

17 Seok Hoo Jeong, "Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C" 대한간학회 18 (18): 360-367, 2012

18 European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of hepatitis C virus infection" 55 : 245-264, 2011

19 Fischer J, "Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection" 55 : 1700-1710, 2012

20 Yoshida H, "Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C" 53 : 425-430, 2004

21 Sinn DH, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients" 26 : 1374-1379, 2011

22 Shiratori Y, "Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival" 142 : 105-114, 2005

23 Yu ML, "A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan" 11 : 985-994, 2006